A Large, High-Secreting Pheochromocytoma: Phenoxybenzamine or Doxazosin for Preoperative Prep
A single patient with an unusually large, high-secreting pheochromocytoma, whose case sits outside the typical patient either major alpha-blocker trial actually enrolled.
Yusuf T., a 46-year-old long-haul truck driver, was diagnosed with a 6.1 cm right adrenal pheochromocytoma after an episode of chest pain and profuse sweating at a truck stop sent him to an emergency department three states from home. He has driven the same regional route for eleven years and describes the episode, half-joking, as the first time his own body ever made him pull over. His plasma normetanephrine came back at fourteen times the upper limit of normal — a genuinely large, high-secreting tumor, not a borderline or incidental one — and he is now three weeks from a planned laparoscopic adrenalectomy, in the window where the actual disagreement about his case lives: which alpha-blocker should carry him through preoperative preparation.
Phenoxybenzamine, a nonselective, irreversible alpha-blocker, has been the traditional standard, but the only randomized trial to compare it directly against a selective alternative — PRESCRIPT, 134 patients — found no significant difference in its primary endpoint, the percentage of intraoperative time spent outside blood pressure targets, between phenoxybenzamine and doxazosin. Phenoxybenzamine did show modestly better hemodynamic stability on a secondary measure, and costs roughly a hundred times more per day — a real consideration for Yusuf specifically, who mentioned his high-deductible insurance plan before either drug was even named. Zawadzka et al.'s 2026 retrospective study specifically complicates the "they're equivalent" reading further: patients prepared with doxazosin had significantly longer intraoperative hypertensive crises and needed vasopressor support more often than those prepared with phenoxybenzamine, with a longer hospital stay to match. Neither trial was designed around tumor size or catecholamine burden specifically, which is exactly the variable Yusuf's case pushes hardest on.
Pre-operative planning, three weeks before adrenalectomy
Zawadzka's 2026 retrospective on this found doxazosin-prepared patients had significantly longer hypertensive crises intraoperatively and needed vasopressors more often. That's not a hypothetical concern for a 6.1 cm tumor with normetanephrine fourteen times normal — that's exactly the operating-room scenario I'd want to avoid. I'd prepare him with phenoxybenzamine.
PRESCRIPT is still the actual randomized trial here, and its prespecified primary endpoint — time outside blood pressure target — showed no significant difference between the two drugs. A later retrospective study is real evidence, but it's a weaker design than an RCT, and I don't think it should override PRESCRIPT's own primary result, especially against a hundredfold cost difference and a materially worse side-effect profile with phenoxybenzamine.
And there is a cost on the other side that hasn't been named yet. He drives for a living, on a high-deductible plan, and phenoxybenzamine's orthostatic hypotension and reflex tachycardia are what three weeks of titration will actually feel like to him — before the hundredfold price difference is counted. A single retrospective study does not outweigh the randomized trial that was built to answer this question, and it certainly doesn't outweigh it for free.
Neither of you is wrong about the evidence — I'd just point out that neither PRESCRIPT nor the 2026 study was built around tumor size or catecholamine burden, and Yusuf's numbers put him well outside a typical enrolled patient in either one. I don't need this to be a global policy question. For a tumor this large and this catecholamine-rich, I'd rather prepare him with the agent that has even a signal of better hemodynamic blunting, and revisit the cheaper, better-tolerated option for the next patient whose tumor looks nothing like his.
Agreed: prepare Yusuf with phenoxybenzamine given his tumor size and catecholamine burden, with beta-blockade added only once alpha-blockade is adequate, and plan for aggressive volume support around surgery.
Not agreed: whether tumor size and catecholamine level should become a formal, written threshold for choosing between the two agents in future cases, or whether this remains a case-by-case judgment call. The anesthesiologist favors a concrete cutoff the whole group could use going forward; the pharmacologist is wary of enshrining a threshold drawn from a single retrospective study into standing practice.